Media coverage about LivaNova (NASDAQ:LIVN) has been trending somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. LivaNova earned a coverage optimism score of 0.21 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.7829795928907 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

A number of equities analysts have commented on the stock. Canaccord Genuity boosted their target price on shares of LivaNova from $76.00 to $81.00 and gave the stock a “hold” rating in a report on Tuesday, February 27th. BidaskClub downgraded shares of LivaNova from a “buy” rating to a “hold” rating in a report on Saturday, March 10th. Needham & Company LLC reiterated a “buy” rating and issued a $104.00 target price (up from $97.00) on shares of LivaNova in a report on Wednesday, February 28th. Zacks Investment Research downgraded shares of LivaNova from a “hold” rating to a “strong sell” rating in a report on Thursday, January 25th. Finally, ValuEngine upgraded shares of LivaNova from a “hold” rating to a “buy” rating in a report on Friday, February 2nd. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $81.43.

How to Become a New Pot Stock Millionaire

LivaNova (LIVN) opened at $85.60 on Friday. LivaNova has a fifty-two week low of $48.58 and a fifty-two week high of $92.31. The company has a current ratio of 2.14, a quick ratio of 1.79 and a debt-to-equity ratio of 0.03. The stock has a market cap of $4,187.76, a PE ratio of -158.52, a PEG ratio of 2.71 and a beta of 0.75.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, February 28th. The company reported $0.88 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.78 by $0.10. LivaNova had a negative net margin of 2.10% and a positive return on equity of 9.37%. The firm had revenue of $278.40 million for the quarter, compared to the consensus estimate of $278.48 million. During the same quarter in the prior year, the company posted $0.83 earnings per share. The company’s revenue for the quarter was up 11.5% compared to the same quarter last year. sell-side analysts forecast that LivaNova will post 3.2 EPS for the current year.

In other news, Director Daniel Jeffrey Moore sold 1,000 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $83.32, for a total transaction of $83,320.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider David S. Wise sold 1,500 shares of the company’s stock in a transaction dated Thursday, March 15th. The shares were sold at an average price of $88.17, for a total transaction of $132,255.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 4,500 shares of company stock worth $386,035. Corporate insiders own 0.28% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “LivaNova (LIVN) Receiving Somewhat Positive Press Coverage, Study Finds” was originally published by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.watchlistnews.com/livanova-livn-receiving-somewhat-positive-press-coverage-study-finds/1958530.html.

LivaNova Company Profile

LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.

Insider Buying and Selling by Quarter for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.